Natural Resources for Human Health
eISSN: 2583-1194

Original Research

Received 18 July 2026
Revised 21 Aug 2026
Accepted 05 Sep 2026

Natural Resources for Human Health 2026, Vol. 6 (21s): 469–477

KEYWORDS:
Clinical pharmacy, Diabetes mellitus, Pharmacist-led intervention, Glycemic control, HbA1c, & Medication therapy management.

Clinical Pharmacy Interventions in the Management of Diabetes Mellitus: A Narrative Review Study

Sumia Farid[1], Samah Alamin[2]*, Mohammed Fahad Almutairi[3], Asim Mansour Al-Harbi[3], Assaf Dhaifallah Al-Mutairi[3], Abdulaziz Ibrahim Al-Adad[3], Owead Sultan Aeed Mutairiy[4], Huyam Mohamedahmed[5], Siham Mohammed Adam[6], Amna Alfadol. M. Abdalla[6], Samah Ahmed[7], Sabir A. Abuelnour[8], Mawaheb Alameen[9]

[1]Department of Pharmaceutics, Faculty of Pharmacy, Elrazi University, Khartoum 11115, Sudan
[2]The Royal Hospital, P.O. Box 1331, Postal Code 111, Seeb, Muscat, Sultanate of Oman.
[3]Pharm D, Pharmacy Department, College of Dentistry and Pharmacy, Buraydah Private Colleges, Buraydah-51418, Al-Qassim, Saudi Arabia
[4]Pharmacy Technicians, Northern Area Armed Forces Hospital (NAAFH), King Khalid Military City, P.O. Box 10018, Hafar Al Batin-31991, Saudi Arabia
[5]Medical Doctor and Health Insurance Claims Specialist, Al Rajhi Takaful, Riyadh, Saudi Arabia
[6]Department of Nursing, College of Applied Medical Sciences, Buraydah Private Colleges, Buraydah-51418, Al-Qassim, Saudi Arabia
[7]Medical Quality Manager, Bupa Arabia, Jeddah, Saudi Arabia
[8]Department of Nursing Sciences, College of Applied Medical Sciences, Shaqra University, Shaqra, Saudi Arabia
[9]Pharmaceutical Scientist, Al Iman General Hospital, Al Mansoura, Riyadh 12684, Saudi Arabia
*Corresponding author: Dr. Samah Alamin,
Email: samahabdulmunim@gmail.com

ABSTRACT:

Background: Diabetes mellitus is a chronic metabolic disorder requiring long-term pharmacological treatment, lifestyle modification, regular monitoring, and patient education. Despite the availability of effective glucose-lowering medications, inadequate glycemic control, poor medication adherence, drug-related problems, and treatment complexity remain important challenges. Clinical pharmacists can contribute to multidisciplinary diabetes care through medication therapy management, patient counselling, adherence support, and identification of medication-related risks.

Objective: To review the role and effectiveness of clinical pharmacy interventions in diabetes management, with particular emphasis on glycemic control, medication adherence, prevention of adverse drug events, patient education, and emerging models of pharmaceutical care.

Methods: This narrative review draws on published systematic reviews, meta-analyses, clinical studies, and professional guidelines addressing pharmacist-led diabetes care.

Natural Resources for Human Health
eISSN: 2583-1194

Relevant literature was identified through searches of PubMed, PubMed Central, and accessible professional guideline sources. Evidence was synthesized narratively according to major intervention categories. This was not a systematic review, and no formal risk-of-bias assessment or pooled statistical analysis was performed.

Results: Published evidence indicates that pharmacist-led interventions can improve glycemic control, medication adherence, self-management practices, and selected cardiovascular risk factors. Effective interventions commonly include medication review, individualized counselling, identification of drug-related problems, follow-up consultations, and collaboration with prescribers. Pharmacists may also contribute to insulin education, hypoglycemia prevention, and appropriate monitoring of patients receiving complex treatment regimens. However, the magnitude of benefit varies across studies, and the independent contribution of individual intervention components remains uncertain.

Conclusion: Clinical pharmacy services can strengthen comprehensive diabetes management by integrating medication optimization with patient education and ongoing monitoring. Their implementation may be particularly valuable in primary care and resource-constrained settings. Future research should evaluate standardized intervention models, long-term clinical outcomes, cost-effectiveness, and implementation strategies appropriate to the Indian healthcare system.

1. INTRODUCTION

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion, reduced insulin action, or a combination of both. The condition is associated with substantial long-term morbidity, including cardiovascular disease, chronic kidney disease, diabetic retinopathy, peripheral neuropathy, and lower-extremity complications. Effective management therefore requires more than glucose-lowering medication alone; it involves continuous assessment, lifestyle modification, prevention of complications, and sustained patient engagement [1]. The global burden of diabetes has increased considerably. The World Health Organization reported that the number of people living with diabetes rose from approximately 200 million in 1990 to 830 million in 2022. The burden is particularly important in low- and middle-income countries, where access to diagnosis, treatment, monitoring, and continuing care may be inconsistent [1].

Pharmacological treatment of diabetes has become increasingly complex. Available therapies include biguanides, sulfonylureas, dipeptidyl peptidase-4 inhibitors, sodium–glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, thiazolidinediones, and insulin preparations. Treatment selection depends on glycemic targets, cardiovascular and renal status, body weight, hypoglycemia risk, adverse effects, affordability, and patient preferences [2]. These factors create opportunities for clinical pharmacists to support safe and effective medication use. Medication-related challenges are common in long-term diabetes care. Patients may experience difficulties following complex dosing schedules, understanding treatment instructions, using insulin devices, recognizing hypoglycemia, or obtaining prescribed medications consistently. Polypharmacy and comorbidities can further increase the risk of drug interactions, inappropriate dosing, and adverse effects.

Clinical pharmacy is a patient-oriented discipline that applies pharmacological knowledge to optimize medication therapy and improve therapeutic outcomes. In diabetes care, pharmacists can review prescriptions, identify drug-related problems, educate patients, assess adherence, reinforce lifestyle recommendations, and communicate medication-related concerns to the treating clinician. Evidence from systematic reviews and meta-analyses suggests that pharmacist-led interventions improve glycemic outcomes compared with usual care [3-5,7-9]. Nevertheless, the effects vary according to baseline glycemic control, intervention frequency, healthcare setting, and the services provided. This narrative review examines the major clinical pharmacy interventions used in diabetes management, their supporting evidence, practical limitations, and future applications.

Natural Resources for Human Health
eISSN: 2583-1194

2. OVERVIEW OF DIABETES MANAGEMENT AND THE ROLE OF CLINICAL PHARMACY

2.1 Individualized pharmacological treatment

The management of diabetes requires individualized treatment rather than a uniform medication strategy. In type 1 diabetes, insulin replacement is essential. In type 2 diabetes, treatment may involve lifestyle interventions, oral glucose-lowering medications, injectable therapies, or combinations of these approaches Current professional guidance emphasizes person-centred selection of therapy and consideration of cardiovascular disease, heart failure, chronic kidney disease, obesity, hypoglycemia risk, adverse effects, treatment burden, and affordability [2]. Clinical pharmacists can contribute by reviewing the prescribed regimen against the patient's clinical profile and identifying issues that warrant further assessment. Examples include potentially inappropriate doses, duplicate therapy, contraindications, administration errors, and the need for monitoring.

2.2 Pharmaceutical care in diabetes

Pharmaceutical care involves a structured approach to identifying, preventing, and resolving medication-related problems. Its purpose is to ensure that medication therapy is appropriate, effective, safe, and practical for the individual patient. A diabetes-focused pharmaceutical care service may include reviewing the complete medication list, including nonprescription medicines and supplements; assessing adherence and barriers to medication use; identifying adverse drug reactions and clinically important interactions; evaluating renal function and other relevant parameters when required for medication safety; providing education about prescribed medicines and administration techniques; reinforcing glucose monitoring and recognition of warning symptoms; communicating identified problems to the treating clinician; and arranging follow-up to assess outcomes and unresolved concerns. These activities transform medication dispensing into an ongoing clinical service focused on therapeutic outcomes.

Table 1: Clinical pharmacy interventions and their expected contributions to diabetes care.

Intervention	Key activities	Expected contribution
Medication therapy review	Assess indication, effectiveness, dose, interactions, contraindications, and monitoring.	Identify and resolve medication-related problems.
Adherence support	Explore barriers; provide reminders and practical dosing instructions.	Support consistent use of prescribed therapy.
Diabetes education	Explain medicines, glucose monitoring, lifestyle measures, and warning symptoms.	Improve knowledge and self-management skills.
Insulin counselling	Demonstrate device technique, injection-site rotation, storage, and disposal.	Reduce administration errors and improve safe use.
Hypoglycemia prevention	Review risk factors and educate on recognition and action plans.	Reduce avoidable treatment-related harm.
Follow-up and referral	Review results, adverse effects, and unresolved concerns; communicate with prescribers.	Support continuity and timely clinical reassessment.

3. MAJOR CLINICAL PHARMACY INTERVENTIONS

3.1 Medication therapy management

Medication therapy management is one of the central activities of clinical pharmacy practice in diabetes care. It involves a comprehensive review of medications to assess indication, effectiveness, safety, adherence, and compatibility with the patient's health status. Potential drug-related problems include ineffective treatment, unnecessary duplication, incorrect administration, adverse reactions, inappropriate dosing, and failure to take prescribed medication. Clinical pharmacists can identify these issues and discuss appropriate solutions with patients and prescribers.

For example, a patient receiving multiple glucose-lowering medications may report recurrent episodes of sweating, tremor, or confusion. A medication review may reveal that the symptoms are consistent with hypoglycemia and that the regimen requires clinical reassessment. The pharmacist can identify the potential relationship, educate the patient, and promptly communicate the findings to the treating clinician. Medication review is particularly important in older adults and patients with renal impairment, cardiovascular disease, or multiple comorbidities. These groups may require closer monitoring and individualized treatment decisions.

3.2 Patient education and diabetes self-management

Diabetes self-management requires patients to understand their condition, take medicines correctly, monitor glucose when indicated, follow an appropriate dietary pattern, remain physically active, and recognize complications. Clinical pharmacists can provide structured education through individual consultations, group sessions, printed information, and digital communication. Education should be adapted to the patient's literacy, language, cultural background, treatment regimen, and capacity to implement recommendations.

Important topics include medication purpose, administration schedules, missed-dose instructions, expected adverse effects, storage requirements, and circumstances requiring medical attention. Patients receiving insulin may need additional education about injection technique, site rotation, device use, and safe storage. A systematic review of pharmacist-led self-management interventions included 24 studies and 3,610 participants. The meta-analysis reported a mean HbA1c reduction of 0.71 percentage points compared with control care, alongside improvements in selected self-management and cardiovascular risk measures [4]. A separate meta-analysis also found that pharmacist-led educational interventions improved HbA1c and several self-care activities in adults with type 2 diabetes [9]. These findings support the value of structured patient education, although the effects cannot be attributed to education alone because many interventions combined several pharmaceutical care activities.

3.3 Improving medication adherence

Medication adherence is essential for sustained glycemic control. However, adherence may be affected by medication cost, forgetfulness, fear of adverse effects, complicated regimens, inadequate understanding, treatment fatigue, and difficulty accessing healthcare services. Clinical pharmacists can assess adherence through nonjudgmental interviews, medication reconciliation, refill histories where available, and validated adherence questionnaires. The objective is to identify the reasons for missed or incorrectly administered doses rather than simply instructing patients to comply.

Potential strategies include simplifying dosing schedules in collaboration with prescribers, using pill organizers when appropriate, linking medication use to daily routines, providing written instructions, and arranging follow-up reminders. Patients should also be encouraged to discuss concerns about treatment openly. A systematic review and meta-analysis of 59 studies reported improvements in medication-related outcomes following pharmacist-led interventions. Educational approaches, written or digital information, and structured discussions were among the intervention strategies associated with benefit [5]. The success of adherence interventions depends on the underlying barrier. Reminder systems may help forgetful patients but are unlikely to resolve unaffordable treatment, adverse effects, or inadequate access to medicines. Effective pharmaceutical care therefore requires individualized assessment.

3.4 Glycemic monitoring and interpretation of HbA1c

HbA1c reflects average glycemic exposure over approximately two to three months and is commonly used to assess longer-term glycemic control. Blood glucose monitoring provides additional information about daily patterns and can help identify hypoglycemia or hyperglycemia. Clinical pharmacists can reinforce appropriate monitoring schedules, explain the purpose and limitations of HbA1c testing, and help patients maintain understandable records of glucose readings. They can also identify results that warrant communication with the treating clinician. A meta-analysis of 12 studies published in 2022 found that pharmacist-led interventions in primary care significantly improved HbA1c compared with usual care, with a standardized mean difference of −0.67 (95% confidence interval −0.87 to −0.48) [3]. The review included randomized and quasi-experimental studies, and heterogeneity between studies was substantial. These findings indicate that pharmacist involvement can contribute to better glycemic control. However, standardized mean differences should not be interpreted directly as absolute percentage-point reductions in HbA1c.

3.5 Insulin education and administration support

Insulin treatment requires correct product selection, dosing, timing, administration technique, storage, and recognition of hypoglycemia. Errors in any of these areas may compromise safety or treatment effectiveness. Clinical pharmacists can educate patients on insulin pen or syringe use, injection-site rotation, appropriate storage, needle disposal, and adherence to the prescribed schedule. They can also review whether patients understand the relationship between insulin administration, meals, physical activity, and glucose monitoring.

Patients should be taught to recognize hypoglycemia, including sweating, trembling, hunger, palpitations, dizziness, confusion, and other relevant symptoms. Education should include an individualized action plan and instructions for obtaining urgent assistance when severe symptoms occur. Insulin dose changes must be based on clinical assessment and the applicable prescribing arrangements. Pharmacists should not encourage patients to alter doses independently unless they have been specifically trained and authorized to provide protocol-based dose adjustment.

3.6 Prevention and management of hypoglycemia

Hypoglycemia is an important adverse outcome of diabetes treatment, particularly in patients using insulin or insulin secretagogues such as sulfonylureas. Clinical pharmacists can identify risk factors, including previous hypoglycemic episodes, irregular food intake, excessive medication dosing, impaired renal function, medication errors, and changes in physical activity. Patients should receive clear instructions on symptom recognition and appropriate immediate management.

When a patient experiences recurrent hypoglycemia, the pharmacist should review the medication regimen and circumstances surrounding the episodes. Findings should be communicated promptly to the treating clinician for assessment of potential dose reduction, treatment simplification, or alternative therapy. Professional guidance recommends reassessing medications associated with hypoglycemia when a new glucose-lowering drug is introduced [2]. Such review may reduce avoidable treatment-related harm and unnecessary treatment burden.

3.7 Prevention of drug interactions and adverse drug reactions

Patients with diabetes frequently receive medications for hypertension, dyslipidemia, cardiovascular disease, kidney disease, and other comorbidities. The combination of multiple medicines can increase the potential for interactions and adverse effects Clinical pharmacists can review the complete medication list and identify clinically significant combinations requiring monitoring or intervention. They should also assess whether medication doses remain appropriate when renal function changes or new comorbidities develop.

For example, patients receiving glucose-lowering medicines that increase hypoglycemia risk may require closer monitoring when food intake decreases or another medicine is introduced. Patients receiving sodium–glucose cotransporter-2 inhibitors should be counselled about relevant warning symptoms, sick-day precautions, and the circumstances in which urgent medical assessment is required. Pharmacists can document suspected adverse drug reactions, recommend appropriate monitoring, and support medication reconciliation during transitions between hospital and community care.

3.8 Lifestyle counselling and cardiovascular risk reduction

Lifestyle modification remains an important component of diabetes management. Pharmacists can reinforce advice on healthy eating, regular physical activity, weight management, tobacco avoidance, and attendance at recommended follow-up appointments. Counselling should be practical and individualized. Rather than providing broad instructions, pharmacists can help patients identify achievable behavioural goals and discuss barriers to implementation. Clinical pharmacists can reinforce the importance of blood pressure and lipid management, kidney monitoring, foot care, and recommended eye examinations.

These activities complement rather than replace assessment by the appropriate healthcare professional. Evidence from randomized trials indicates that pharmacist interventions can improve cardiovascular risk factors, including blood pressure and lipid measures, in people with diabetes [10]. The selection of glucose-lowering therapy increasingly considers benefits beyond HbA1c reduction. Current American Diabetes Association guidance recommends consideration of agents with demonstrated cardiovascular or kidney benefits in appropriate patients with relevant comorbidities [2]. Pharmacists can support safe use of these medicines through counselling, monitoring, and identification of treatment-related concerns.

Table 2: Selected published evidence on pharmacist-led diabetes care.

Evidence source	Scope	Reported finding	Interpretation / limitation
Coutureau et al. [3], 2022	Systematic review/meta-analysis; 12 studies in primary care	HbA1c standardized mean difference −0.67 (95% CI −0.87 to −0.48).	Favours pharmacist-led care; standardized effect is not an absolute HbA1c percentage-point change.
Van Eikenhorst et al. [4], 2017	Systematic review/meta-analysis; 24 studies, 3,610 participants	Reported mean HbA1c reduction of 0.71 percentage points (95% CI −0.91 to −0.51).	Interventions were multicomponent; effect cannot be attributed to education alone.
Presley et al. [5], 2019	Systematic review/meta-analysis of pharmacy-led adherence interventions	Reported improvements in medication adherence-related outcomes.	Specific effects depend on intervention and adherence measure; verify full bibliographic details.
Jeong et al. [6], 2018	Systematic review/meta-analysis of pharmaceutical care studies	Reported improved glycemic control compared with usual care.	Study designs and interventions varied; full citation details should be checked before submission.

Abbreviations: HbA1c, glycated haemoglobin; CI, confidence interval. This table summarizes selected published reviews and is not a new pooled analysis.

4. EVIDENCE FOR THE EFFECTIVENESS OF CLINICAL PHARMACY INTERVENTIONS

Published systematic reviews and meta-analyses provide evidence that pharmacist-led diabetes care can improve glycemic control. Reviews of outpatient pharmacist interventions report improvements in glycemic and other clinical outcomes, although intervention designs and outcome measures differ across studies [7-8]. Coutureau and colleagues included 12 articles in a systematic review and meta-analysis of pharmacist-led interventions in primary care. The pooled standardized mean difference in HbA1c change favoured pharmacist intervention, at −0.67 (95% CI −0.87 to −0.48) [3]. A separate systematic review of 24 studies involving 3,610 patients found a mean HbA1c reduction of 0.71 percentage points (95% CI −0.91 to −0.51) with pharmacist-led self-management interventions [4].




Figure 1: Pooled HbA1c reduction reported for pharmacist-led self-management interventions.

(Note: The estimate and 95% confidence interval are reproduced from the published systematic review [4]).

Another meta-analysis examining pharmaceutical care included 37 studies and reported a statistically significant improvement in HbA1c outcomes compared with usual care. The authors also noted that intervention duration and differences between

healthcare settings influenced the interpretation of results [6]. Collectively, these findings support pharmacist participation in diabetes management. Nevertheless, the evidence should be interpreted carefully. Interventions frequently combine medication review, counselling, adherence support, and follow-up, making it difficult to determine the independent contribution of each component. Differences in baseline HbA1c, patient characteristics, intervention intensity, study duration, and usual-care practices also contribute to variation in reported outcomes. Improvements in HbA1c do not automatically establish reductions in long-term complications, hospital admissions, or mortality. These outcomes require appropriate longitudinal studies.

5. DIGITAL HEALTH AND TELEPHARMACY

Digital technologies provide additional opportunities to extend clinical pharmacy services. Telephone consultations, secure messaging, electronic medication records, glucose-monitoring platforms, and telepharmacy may support communication between patients and healthcare professionals. Remote follow-up can be particularly useful for patients who have difficulty attending frequent appointments. Pharmacists may use these services to review adherence concerns, reinforce medication instructions, discuss reported adverse effects, and encourage appropriate follow-up testing.

Digital interventions should be selected according to patient needs and access to technology. Limited internet access, low digital literacy, language barriers, privacy concerns, and unreliable data entry may reduce effectiveness. Remote services should also have clear procedures for identifying urgent symptoms and referring patients for in-person assessment. Digital tools are best regarded as additions to individualized pharmaceutical care rather than replacements for clinical examination or comprehensive diabetes management.

6. BARRIERS TO IMPLEMENTING CLINICAL PHARMACY SERVICES

Despite the potential benefits, several barriers can limit the implementation of clinical pharmacy services in diabetes care. First, the availability of pharmacists with clinical training and access to appropriate facilities may vary between healthcare settings. Second, limited consultation time and high patient workloads can restrict opportunities for detailed counselling and follow-up. Third, unclear professional roles and inadequate communication between pharmacists and prescribers may prevent identified medication problems from being resolved. Structured referral pathways and collaborative practice arrangements can help address this challenge.

Fourth, patient-related factors including affordability, health literacy, language, treatment fatigue, and transport difficulties may reduce engagement with pharmaceutical care. Finally, the cost-effectiveness of individual service models may differ according to staffing requirements, intervention intensity, local medicine prices, and healthcare infrastructure. Implementation should therefore consider both clinical effectiveness and practical feasibility.

7. RELEVANCE TO THE INDIAN HEALTHCARE SYSTEM

Clinical pharmacy interventions may be particularly relevant in India, where diabetes care involves diverse public and private healthcare settings and substantial variation in access to monitoring and continuing professional support. Pharmacists may help patients understand medication schedules, recognize adverse effects, use insulin devices correctly, and maintain follow-up. Counselling in local languages and the use of simple written instructions may improve understanding among patients with different educational backgrounds.

Affordability should be addressed through discussion of prescribed treatment options, access to medicines, and adherence barriers. Any proposed substitution or change in therapy must be consistent with applicable regulations and coordinated with the authorized prescriber. Community pharmacies may provide convenient opportunities for medication education and referral, while hospital-based clinical pharmacists can contribute to medication reconciliation, inpatient treatment review, discharge counselling, and continuity of care. However, findings from international studies cannot be assumed to apply uniformly to all Indian settings. Local implementation studies are needed to assess acceptability, staffing requirements, patient outcomes, and economic feasibility.

1. Patient assessment **Medication list • HbA1c/glucose records • adherence • comorbidities • patient priorities**
↓
2. Individualized pharmacy intervention **Medication review • education • adherence support • insulin technique • safety counselling**
↓
3. Follow-up and outcome evaluation **Review response and adverse effects • document outcomes • communicate with prescriber • refer when needed**

Figure 2: Framework for pharmacist-led diabetes care.

(Note: This conceptual framework summarizes common clinical pharmacy activities; it is not a validated clinical pathway).

8. Future Perspectives

Future clinical pharmacy services should move toward structured, measurable, and patient-centred models of care. First, standardized documentation of medication-related problems and interventions would improve continuity and evaluation. Second, pharmacists should receive continuing training in diabetes pharmacotherapy, insulin education, medication safety, and communication with multidisciplinary teams. Third, digital follow-up systems may support ongoing adherence assessment and timely referral. Their implementation should account for privacy, accessibility, and differences in digital literacy.

Fourth, future studies should evaluate not only HbA1c but also hypoglycemia, medication adherence, treatment satisfaction, quality of life, healthcare utilization, and cost-effectiveness. Longer follow-up periods are needed to determine whether improvements in intermediate outcomes translate into sustained clinical benefits. Finally, research in India should examine which intervention components are most effective in different healthcare settings and whether structured clinical pharmacy services can be implemented sustainably within existing healthcare resources.

9. LIMITATIONS OF THE REVIEW

The underlying studies varied in design, population, intervention content, duration, and outcome measurement. Consequently, the findings support the general value of clinical pharmacy interventions but do not establish that every intervention is equally effective or that the reported improvements will occur in all healthcare settings.

10. CONCLUSION

Clinical pharmacy interventions can contribute meaningfully to diabetes management through medication therapy management, patient education, adherence support, insulin counselling, prevention of hypoglycemia, and identification of drug-related problems. Published systematic reviews and meta-analyses generally support improvements in glycemic control and selected patient-related outcomes following pharmacist-led care. The greatest practical value is likely to arise when pharmacists provide individualized support, maintain communication with prescribers, and participate in continuing follow-up rather than delivering isolated educational sessions. In India, integrating appropriately trained clinical pharmacists into multidisciplinary diabetes services may improve medication safety and continuity of care. Further local research is required to establish the most effective, feasible, and cost-effective models for different healthcare settings.

DECLARATIONS

Funding

No external funding was received for this work.

Conflict of Interest

The author declares no conflict of interest.

Ethics Approval

Ethics approval was not required because this narrative review synthesized previously published literature and involved no human participants or identifiable patient data.

Author contributions

The initial drafts of the manuscript were co-developed by the primary author and the corresponding author, who provided overall research supervision and conceptual guidance. Each co-author played an active role throughout the lifecycle of the study, contributing substantially to data acquisition, critical writing, structural revisions, and the formulation of analytical tables. Following iterative rounds of review and refinement, all authors formally approved the final text and authorized its submission to the journal for consideration.

Acknowledgement

The authors wish to extend their sincere gratitude to the administrators, curators, and indexing services of the databases that facilitated this literature review, including PubMed, MEDLINE, Embase, Google Scholar, the Cochrane Library, the Directory of Open Access Journals (DOAJ), and BMJ Clinical Evidence. Their comprehensive indexing, digital infrastructure, and commitment to open-access scholarly publishing provided vital access to primary peer-reviewed literature, clinical trials, and systematic reviews essential to the completion of this study.

REFERENCES

[1] World Health Organization. Diabetes. Fact sheet. 14 November 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes

[2] American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1): S183–S215. doi:10.2337/dc26-S009.

[3] Coutureau C, Slimano F, Mongaret C, Kanagaratnam L. Impact of Pharmacists-Led Interventions in Primary Care for Adults with Type 2 Diabetes on HbA1c Levels: A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health. 2022;19(6):3156. doi:10.3390/ijerph19063156.

[4] van Eikenhorst L, Taxis K, van Dijk L, de Gier H. Pharmacist-Led Self-management Interventions to Improve Diabetes Outcomes: A Systematic Literature Review and Meta-Analysis. Front Pharmacol. 2017; 8: 891. doi:10.3389/fphar.2017.00891.

[5] Presley B, Groot W, Pavlova M. Pharmacy-led interventions to improve medication adherence among adults with diabetes: A systematic review and meta-analysis. Res Social Adm Pharm. 2019;15(9):1057–1067. doi:10.1016/j.sapharm.2018.09.021.

[6] Jeong S, Lee M, Ji E. Effect of pharmaceutical care interventions on glycemic control in patients with diabetes: A systematic review and meta-analysis. Ther Clin Risk Manag. 2018;14:1813–1829. doi:10.2147/TCRM.S169748.

[7] Pousinho S, Morgado M, Falcão A, Alves G. Pharmacist Interventions in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials. J Manag Care Spec Pharm. 2016;22(5):493–515. doi:10.18553/jmcp.2016.22.5.493.

[8] Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008;28(4):421–436. doi:10.1592/phco.28.4.421.

[9] Bukhsh A, Tan XY, Chan KG, Lee LH, Goh BH, Khan TM. Effectiveness of pharmacist-led educational interventions on self-care activities and glycemic control of type 2 diabetes patients: a systematic review and meta-analysis. Patient Prefer Adherence. 2018; 12:2457–2474. doi:10.2147/PPA.S180256.

[10] Santschi V, Chiolero A, Paradis G, Colosimo AL, Burnand B. Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2012;35(12):2706–2717. doi:10.2337/dc12-0369.